Literature DB >> 2590599

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.

C Ged1, J M Rouillon, L Pichard, J Combalbert, N Bressot, P Bories, H Michel, P Beaune, P Maurel.   

Abstract

1. Urinary excretion of 6 beta-hydroxycortisol, hepatic microsomal cortisol 6 beta-hydroxylase and the specific content of several forms of cytochrome P450 were measured in 8 to 14 patients before and after treatment with rifampicin (600 mg orally per day for 4 days). 2. Rifampicin treatment produced an average five fold increase in daily excretion of urinary 6 beta-hydroxycortisol. 3. Cortisol 6 beta-hydroxylase activity increased from 15 +/- 6 pmol min-1 mg-1 in organ donors (considered as 'control subjects') to 87 +/- 31 pmol min-1 mg-1 in rifampicin treated patients. 4. Among three forms of human P450 (P450IA, IIC and IIIA), (1), (2), measured by Western blots, only P450IIIA was significantly induced by the antibiotic. 5. Only antibodies against P450IIIA selectively inhibited cortisol 6 beta-hydroxylase in human liver microsomes. 6. Cortisol 6 beta-hydroxylase was correlated with P450IIIA specific content. 7. The urinary level of 6 beta-hydroxycortisol correlated with liver microsomal cortisol 6 beta-hydroxylase and P450IIIA specific content. 8. We conclude that P450IIIA is predominantly responsible for cortisol 6 beta-hydroxylase activity in human liver microsomes and that urinary 6 beta-hydroxycortisol is a marker of the induction of this cytochrome P450.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590599      PMCID: PMC1379986          DOI: 10.1111/j.1365-2125.1989.tb03516.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  64 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Radioactive assay for aryl hydrocarbon hydroxylase. Improved method and biological importance.

Authors:  J Van Cantfort; J De Graeve; J E Gielen
Journal:  Biochem Biophys Res Commun       Date:  1977-11-21       Impact factor: 3.575

3.  Immunochemical characterization of some monooxygenase activities in liver microsomes from untreated and phenobarbital-treated rats.

Authors:  E Le Provost; J P Flinois; P Beaune; J P Leroux
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

4.  A direct enzyme immunoassay of 6 beta-hydroxycortisol in human urine.

Authors:  H Hosoda; Y Sakai; T Nambara
Journal:  Chem Pharm Bull (Tokyo)       Date:  1981-01       Impact factor: 1.645

5.  Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene.

Authors:  M D Burke; R T Mayer
Journal:  Drug Metab Dispos       Date:  1974 Nov-Dec       Impact factor: 3.922

6.  A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.

Authors:  B K Park
Journal:  J Steroid Biochem       Date:  1978-10       Impact factor: 4.292

7.  Quantitative determination by HPLC of urinary 6beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs.

Authors:  I Roots; R Holbe; W Hövermann; S Nigam; G Heinemeyer; A G Hildebrandt
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

8.  Cytochrome P-450 monooxygenase activities in human and rat liver microsomes.

Authors:  P Kremers; P Beaune; T Cresteil; J de Graeve; S Columelli; J P Leroux; J E Gielen
Journal:  Eur J Biochem       Date:  1981-09-01

9.  Radioimmunoassay of 6beta-hydroxycortisol in human plasma and urine.

Authors:  S Kishida; D K Fukushima
Journal:  Steroids       Date:  1977-12       Impact factor: 2.668

10.  6 beta-Hydroxycortisol: a noninvasive indicator of enzyme induction.

Authors:  P Saenger; E Forster; J Kream
Journal:  J Clin Endocrinol Metab       Date:  1981-03       Impact factor: 5.958

View more
  59 in total

1.  Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.

Authors:  P Damkier; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.

Authors:  N B Glazer; W W Cheatham
Journal:  BMJ       Date:  2001-01-27

3.  The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.

Authors:  S Saima; K Furuie; H Yoshimoto; J Fukuda; T Hayashi; H Echizen
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

4.  Occupational exposure to cis-1,3-dichloropropene: biological effect monitoring of kidney and liver function.

Authors:  A J Verplanke; L J Bloemen; E J Brouwer; P J Boogaard; R F Herber
Journal:  Occup Environ Med       Date:  2000-11       Impact factor: 4.402

5.  Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4.

Authors:  Qian Cheng; Christal D Sohl; Francis K Yoshimoto; F Peter Guengerich
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

Review 6.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

7.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

8.  Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.

Authors:  C-C Peng; I Templeton; K E Thummel; C Davis; K L Kunze; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2011-04-13       Impact factor: 6.875

9.  Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.

Authors:  Kwee Poo Yeo; Stephen L Lowe; Ming Tung Lim; James R Voelker; Jennifer L Burkey; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

10.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.